Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 3Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 7Recurrence 2Leukemia 2

Interventions

Cyclophosphamide 178Cytarabine 110fludarabine phosphate 102Methotrexate 98Busulfan 90Filgrastim 80Rituximab 72Peripheral Blood Stem Cell Transplantation 69Cyclosporine 60Radiotherapy 57Etoposide 57Mycophenolic Acid 56Antilymphocyte Serum 56fludarabine 55Tacrolimus 55Vincristine 47Whole-Body Irradiation 44Melphalan 42Dexamethasone 39Granulocyte Colony-Stimulating Factor 38sargramostim 34Methylprednisolone 34Alemtuzumab 34Daunorubicin 33Imatinib Mesylate 32Mercaptopurine 28Prednisone 26Idarubicin 26Doxorubicin 25Leucovorin 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Leukemia × quizartinib × Clear all
NCT06824168 2025-12-04

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Daiichi Sankyo

Phase 2 Recruiting
130 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT00989261 2019-12-11

ACE

Daiichi Sankyo

Phase 2 Completed
333 enrolled 23 charts
Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡